News

The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs will be co-preferred options

The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.

May 28 () - CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some ‌of its drug lists as an additional preferred option ‌for insurance coverage. Caremark, CVS' pharmacy benefit management unit, had dropped Zepbound from coverage ​on July 1 last year, while continuing to reimburse for rival Novo Nordisk's Wegovy after negotiating a more favorable price from the Danish drugmaker.

Truist called Viking a “differentiated player” in the crowded obesity market, highlighting its flagship VK2735 candidate and dual oral-plus-injectable GLP-1 strategy.

Novo Nordisk A/S (NYSE:NVO) is one of the Most Undervalued Foreign Stocks to Buy Now. On May 6, Reuters reported that Novo Nordisk A/S (NYSE:NVO) topped first-quarter profit forecasts and also raised the full-year outlook slightly. The results were driven by the company’s new Wegovy weight-loss pill, which was launched in the US in January. […]

Eli Lilly (LLY) stock has surged to new record highs of over $1,000 a share, cementing its position as one of the market's most dominant growth stories and the first pharmaceutical firm worth $1 trillion.

There is no reason to panic just yet.

Hims & Hers Health shares have slumped in 2026 as the telehealth provider moves away from selling compounded GLP-1 medications.

NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock comparison.

BofA cut its HIMS price target to $25 from $28, while warning that the company’s 2026 outlook depends on a “significant” ramp-up in GLP-1 growth.

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index shedding 0.7% an

Hims & Hers Health (NYSE: HIMS) faces a demanding customer acquisition challenge to hit its 2026 revenue guidance amid rising churn risks tied to its oral Wegovy subscription model, Bank of America said. Analysts estimate HIMS would need to add approximately 225,000 new oral Wegovy...

Novo Nordisk (CPSE:NOVO B) reported new findings from its POSEIDON study on cardiovascular inflammation in patients with heart disease. The study highlights a high prevalence of cardiovascular inflammation among patients already receiving treatment for atherosclerotic cardiovascular disease. Results point to an unmet medical need for therapies that can address residual inflammatory risk beyond current standard care. Novo Nordisk, known for its cardiometabolic and related therapies, now has...

Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the

Weight-loss drugs such as Novo Nordisk's Ozempic and Wegovy are disrupting eating habits, and restaurants should prepare for changes, an analyst says. More than half of Americans taking GLP-1 drugs including Eli Lilly's Mounjaro have changed their eating habits, a survey by UBS found. "Our survey results suggest GLP-1 users are more likely to eat less calories while taking GLP-1 drugs, with survey respondents dining out less, changing eating habits, and appreciating healthier foods more," UBS analysts led by Dennis Geiger said in a note to clients.

European equities traded in the US as American depositary receipts were trending higher late Tuesday

Novo Nordisk's EU label expansions may widen semaglutide use and boost volumes, but pricing pressure and Lilly rivalry can limit recovery.

New Cancer Research Could Be a Massive Game Changer for Ozempic and Mounjaro

Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.

Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with all-time volume above $1.68 million on that single contract. The hook is obesity. Viking’s VK2735 dual GLP-1/GIP agonist is arguably the most advanced obesity asset not ... If Viking Therapeutics Is Acquired, Here’s Who Wins

In the Large-Cap Pharmaceuticals industry, LLY, J&J, NVO and BAYRY are worth retaining as the industry shows some recovery.

IX, SBUX and GOOGL rallied after Zacks upgrades and portfolio additions, while major indexes stayed volatile amid Fed and inflation concerns.

These players are seeing exciting results in clinical trials.

Novo Nordisk (NYSE:NVO) received a positive opinion from the European Medicines Agency supporting EU approval of its oral Wegovy obesity treatment. The therapy would be the first oral GLP-1 option for obesity in Europe if formally authorized by the European Commission. The development follows a strong U.S. launch for the Wegovy pill and comes ahead of planned international rollouts. Novo Nordisk, known for its diabetes and obesity treatments, is now moving closer to bringing an oral Wegovy...

It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars.

The recent positive opinion from the EMA’s Committee for Medicinal Products for Human Use on the Wegovy pill has pushed Novo Nordisk (CPSE:NOVO B) back into focus for investors watching obesity and cardiovascular treatments. See our latest analysis for Novo Nordisk. These Wegovy updates have arrived during a strong short term rebound in Novo Nordisk’s share price, with a 30 day share price return of 11.18% and 90 day return of 18.61%. However, the year to date share price return is down...

The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet.

VEEV's growing Vault CRM adoption and AI momentum, backed by major pharma wins, reinforce confidence in its long-term growth outlook.

NVO's Wegovy pill gets CHMP backing, moving it closer to becoming the first oral GLP-1 treatment approved in the EU for weight management.

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.